Last reviewed · How we verify
NCT02417168
Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study
trial in Cancer in 1 participant. Terminated before completion.
1 March 2016
Quick facts
| Lead sponsor | CAMC Health System |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 1 July 2015 |
| Primary completion | 1 March 2016 |
| Estimated completion | 1 March 2016 |
| Sites | 1 location across United States |
Conditions studied
- Cancer — all drugs for Cancer →
- Bacteremia — all drugs for Bacteremia →
Sponsor
CAMC Health System — full company profile →
Who can join
Under 17, any sex, with Cancer or Bacteremia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fevers raise the concern for serious bacterial infections in pediatric oncology patients receiving chemotherapy. The gold standard for diagnosing bacteremia (bacterial infection of the blood) is a blood culture. However, bacterial growth may not occur for 48 hours or there can be a false negative result. Thus, the biomarker, procalcitonin, has been investigated for its predictive ability to identify bacteremia earlier than blood culture. We believe that procalcitonin can assist in differentiating bacteremia from non-bacteremia infections in febrile pediatric oncology patients. A reliable predictor of bacteremia infections in pediatric oncology patients should decrease hospitalizations for fever and unnecessary antibiotic treatment. In our study we will measure procalcitonin levels in pediatric oncology patients presenting with fever. We will measure procalcitonin at the time of admission which is part of our standard of care for febrile pediatric oncology admissions. For the purpose of our study, we will additionally measure procalcitonin levels at 12 hours and at 24 hours post admission. We will examine procalcitonin levels at these three timepoints to determine if elevated procalcitonin levels predict bacteremia in pediatric oncology patients with and without neutropenia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02417168
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other CAMC Health System trials
Trials by the same sponsor.
- NCT07443254 — Prospective IR-led Sedation Feasibility · Phase 1, PHASE2 · recruiting
- NCT05970354 — EMLA Cream as Analgesic for Outpatient Gynecological Procedures · Phase 4 · enrolling by invitation
- NCT04705480 — Pregabalin vs. Gabapentin on Reducing Opioid Usage · Phase 4 · completed
- NCT04279457 — Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-R · Phase 4 · recruiting
- NCT03565198 — Ferritin as a Predictor for Anemia in Pregnancy · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02417168 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CAMC Health System
- Last refreshed: 4 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02417168.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing